JD Supra11h
Lilly v. FDA: Two Stories Collide to Make this GLP-1 Case a Tale of Our Time
I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...
24/7 Wall St. on MSN13h
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?
Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...
USA Today22d
Off-brand versions of Lilly weight loss drug must be pulled off market, could mean higher prices
The United States Food and Drug Administration says the shortage of Eli Lilly’s ... the need for the off-brand versions. “We conclude that the information and data Lilly has provided to ...
GlobalData on MSN2d
Mediar Therapeutics signs licensing deal with Eli Lilly for IPF treatment
Mediar Therapeutics has entered a global licensing agreement with Eli Lilly and Company to progress the human immunoglobulin ...
Eli Lilly: Still Expensive As Earnings Near, But Not Worthy Of A Downgrade
Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.
CNBC on MSN22d
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions – NBC Los Angeles
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next two to three months.
Lilly asks to join lawsuit over compounded versions of its weight-loss drugs
Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...
Daily1d
Copycat weight-loss drugs: Eli Lilly sues two medical spas
Two medical spas have been sued by Eli Lilly for selling unapproved products that claim to contain tirzepatide. Tirzepatide ...